|  |  |
| --- | --- |
|  | |
| Book Name: | [**Medical Science: Trends and Innovations**](https://www.bookpi.org/bookstore/product/medical-science-trends-and-innovations-vol-1/) |
| Manuscript Number: | **Ms\_BPR\_5013** |
| Title of the Manuscript: | **First cycle treatment in a case of an AML FAB M2 and COVID-19 pneumonia** |
| Type of the Article | **Book Chapter** |

**Special note:**

**A research paper already published in a journal can be published as a Book Chapter in an expanded form with proper copyright approval.**

**Source Article:**

**This chapter is an extended version of the article published by the same author(s) in the following journal.**

**Asian Hematology Research Journal, 4(1): 12-18, 2021.**

**Available:** [**https://journalahrj.com/index.php/AHRJ/article/view/52**](https://journalahrj.com/index.php/AHRJ/article/view/52)

|  |  |  |
| --- | --- | --- |
| PART 1: Comments | | |
|  | Reviewer’s comment **Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer review.** | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | This article describes a case report where an AML patient after heart valve surgery infected by COVID-19, thus complicating the treatment. They also describe patient improvement after Venetoclax was administered alongside the first cycle of chemotherapy. These factors made this case report unique and worthy to be published for a larger scientific and academic audience. |  |
| **Is the title of the article suitable?**  **(If not please suggest an alternative title)** | The title is okay, but here are some suggestion to improve it:  Targeted therapy in AML patient with COVID-19.  Response of targeted therapy alongside chemotherapy in AML patient with COVID-19.  BCL-2 inhibitor therapy and chemotherapy in AML patient with COVID-19. |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | The abstract is quite informative, but the arrangement of the sentences can be improved to make it more comprehensive. |  |
| **Is the manuscript scientifically, correct? Please write here.** | It is scientifically correct, but the patient’s result is based on the real patient because it is a case report. |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.**  **-** | The references are sufficient and recent. If there are more references, can be added also to enrich the discussion part. |  |
| Is the language/English quality of the article suitable for scholarly communications? | The grammar should be corrected with tools like Grammarly.  Some mistakes in typing (typos) should be corrected, and abbreviation should be given the brackets “( )” for explaination/description. |  |
| Optional/General comments | Is it okay to mention brand name in this paper to publish in a scientific book? (Venclexta and Venclyxto) If it is okay with the publisher then no problem.  Revision is needed. Especially the arrangement of sentences in the manuscript. |  |

|  |  |  |
| --- | --- | --- |
| **PART 2:** | | |
|  | Reviewer’s comment | Author’s comment *(if agreed with the reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?** |  |  |

**Reviewers:**

**Putu Dewinta Darmada, Faculty of Medicine Sam Ratulangi University, Indonesia**